Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer
Status:
Withdrawn
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
This is a monocentric prospective non randomized phase 0 clinical trial targeting patients
with colon cancer for whom an upfront surgery has been advised by the pluridisciplinary team.